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Edited by Francesc PosasAbstract Hypoxia-inducible factor-1 (HIF-1) is a transcription
factor that mediates the adaptive response to hypoxia. Increasing
evidence suggests a crucial role for HIF-1 in immune reactions.
Here we investigated the eﬀect of the Th2 type cytokines IL-4
and IL-10 on HIF-1a mediated response in normoxia (21%
O2) and hypoxia (1% O2). Incubation of human transformed
intestinal cells (HT-29) with IL-4 signiﬁcantly increased HIF-
1a protein levels during hypoxia but not during normoxia. Mech-
anisms involved are IL-4 induced up-regulation of HIF-1a gene
transcription and the PI3K signaling pathway. The increase in
hypoxia-induced accumulation of HIF-1a protein after IL-4
treatment did not result in up-regulation of HIF-1 DNA-binding
activity or HIF-1 dependent gene expression. IL-10 did not aﬀect
HIF-1a protein levels.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Phosphatidylinositol-3-kinase1. Introduction
One of the ways by which mammalian cells adapt to hypoxia
is through the up-regulation of the expression of speciﬁc genes
involved in angiogenesis, erythropoiesis, glucose transport,
and glycolysis. These adaptive responses are primarily regu-
lated by the transcription factor, hypoxia inducible factor
(HIF)-1 [1]. HIF-1 is a heterodimer made up of the a and b
(Arnt) subunit, both of which belong to a family of basic
helix-loop-helix PAS (per/arnt/sim) transcription factors [2].
HIF-1b is constitutively expressed, whereas HIF-1a protein
is increased under hypoxic conditions. Under normoxic condi-
tions speciﬁc proline residues of the HIF-1a protein are
hydroxylated, allowing von Hippel-Lindau protein (pVHL)
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prolyl hydroxylation is inhibited and HIF-1a protein accumu-
lates and forms transcriptionally active heterodimers with
HIF-1b. These heterodimers translocate to the nucleus and
induce gene transcription. Transcriptional activity of HIF-1
is regulated by asparaginyl-hydroxylase enzymes. Hydroxyl-
ation of asparagine prevents transcriptional recruitment of
the cofactor CBP/p300 and reduces the transcriptional activity
of HIF-1 during normoxic conditions [5]. During hypoxia
asparagine hydroxylation is also inhibited.
Beside of its role in oxygen homeostasis increasing evidence
suggests an important role for HIF-1 in immune reactions.
Various pro-inﬂammatory cytokines and other inﬂammatory
mediators have been shown to up-regulate HIF-1a protein
expression as well as HIF-1 DNA binding activity under both
normoxic or hypoxic conditions [6–8]. Furthermore, HIF-1
mediates expression of several genes important for inﬂamma-
tory reactions, such as inducible NOS and heme oxygenase-1
[9,10].
Both inﬂammation and hypoxia are believed to be impor-
tant pathogenic factors during sepsis and shock. Decreased
capillary ﬂow and heterogeneity of microvascular perfusion
are characteristics for septic circulatory disturbances [11]. In
the course of sepsis the immune response can shift from a
pro-inﬂammatory towards an anti-inﬂammatory, immunosup-
pressive state which seems to have an adverse eﬀect on out-
come [12,13]. We were therefore interested in investigating
the eﬀect of the type 2 T helper cell (Th2-type) immune re-
sponses on HIF-1. Activated CD4 T cells secrete cytokines
with either inﬂammatory properties (Th1-type immune
response) or anti-inﬂammatory properties (Th2-type immune
response [14,15], e.g. IL-4 and IL-10). Sepsis, burns, and trau-
ma all can ause signiﬁcant increases in IL-4 and IL-10 levels
[14]. Here, we investigated the eﬀect of IL-4 and IL-10 on
HIF-1a protein levels and HIF-1 mediated gene transcription
in intestinal epithelial cells under normoxic and hypoxic con-
ditions.2. Materials and methods
2.1. Cell culture and reagents
All reagents were from Sigma–Aldrich Chemical Co. (St. Louis,
MO) unless otherwise indicated. Cell culture media and reagents were
from PAA Laboratories (Coelbe, Germany). The transformed human
intestinal cell line HT-29 (kindly provided by Prof. Kucharzik, Muen-
ster, Germany) were grown in RPMI 1640 medium containing 10%
fetal bovine serum, 45 U/ml penicillin, and 9 lg/ml streptomycin. Cells
were fed every second day and kept in a humidiﬁed atmosphere of 5%
CO2 in air at 37 C.ation of European Biochemical Societies.
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IL-4 and IL-10 were added to culture media of cells at 90% conﬂu-
ence at a dose of 0.1–100 ng/ml. The cells were incubated for 4 or 13 h
under the following conditions: with or without cytokines, normoxia
(N; 21% O2) or hypoxia (H; 1% O2). Following incubation whole cell
protein, nuclear protein, or RNA were extracted. Eﬀects of hypoxia
were studied in cultures placed in an air tight cell chamber with inﬂow
and outﬂow valves. A hypoxic gas mixture (1% O2, 5% CO2, 94% N2)
was delivered at 6 l/min for 15 min. Oxygen concentration within the
cell chamber was continuously measured with an oxygen sensor (Drae-
ger, Luebeck, Germany). Prior to inhibitor experiments, cells were pre-
incubated with LY204002 (25 lM ﬁnal concentration) or actinomycin
D (0.5 lg/ml ﬁnal concentration) for 20 min each. The ﬁnal DMSO
concentration was 0.5% in the cell cultures prepared for inhibitor
experiments including controls.
2.3. Protein extraction and Western blotting
After incubation, cells were washed with ice-cold PBS and lysed in
extraction buﬀer (Tris 40 mM pH 7.5, KCl 150 mM, EDTA 1 mM,
Triton X-100 1%), supplemented with the protease inhibitor mix Com-
plete Mini 1:25 (Roche Diagnostics), 1 lg/ml pepstatin A, 100 mM
NaVO3, and 100 mM PMSF. The lysate was mixed 10 times on ice
and centrifuged 5 min at 15000 rpm at 4 C. Total protein concentra-
tion was determined using the BCA assay (Pierce, Rockford, IL). Pro-
tein extracts (50 lg) were fractionated by 7.5% polyacrylamide–SDS
gel electrophoresis and transferred onto a polyvinylpyrrolidone diﬂuo-
ride membrane (Roth, Karlsruhe, Germany). The membrane was
blocked with Tris-buﬀered saline (TBS)/5% non-fat milk at 4 C over-
night. Membranes were incubated with anti-HIF-1a mouse mono-
clonal antibody (BD Biosciences, Heidelberg, Germany, 1:1.000) in
TBS/5% non-fat milk for 1 h at room temperature. After three washes
with TBS/5% non-fat milk, membranes were incubated with a second-
ary antibody (sheep anti-mouse IgG horseradish peroxidase-linked
antibody, Amersham Biosciences, Uppsala, Sweden, 1:5.000) for
30 min at room temperature. Enhanced chemiluminescence substrate
(ECL Plus, Amersham, Freiburg, Germany) was used for signal detec-
tion. Equal loading and transfer eﬃciency were veriﬁed by incubation
with anti-actin (A 2066; Sigma, Germany, 1:3.000).
2.4. Nuclear extract preparation
HIF-1a DNA binding activity was determined in nuclear extracts of
HT-29 cells. After incubation cells were washed with ice-cold PBS and
centrifuged at 14000 · g for 10 s. The cell pellet was resuspended in
buﬀer I (10 mM 10 Tris, pH 7.8, 1.5 mM MgCl2, 0.3 M sucrose) and
incubated on ice for 15 min. To lyse cells 0.5% (octylphenoxy)polyeth-
oxyethyl (NP-40) was added. Nuclei were pelleted at 500 · g for 3 min,
resuspended in buﬀer II (10 mM Tris, pH 7.8, 420 mM KCl, 1.5 mM
MgCl2, 20% glycerol), and incubated for 10 min on ice. Immediately
before use, buﬀers I and II were supplemented with 1 mM Na3VO4,
0.5 mM phenylmethylsulfonyl ﬂuoride, 1 mM dithiothreitol, and pro-
tease inhibitor mix Complete Mini 1:25 (Roche Diagnostics). Nuclei
were centrifuged at 14000 · g for 10 min. Protein concentrations were
determined by the Bradford method.
2.5. Colorimetric DNA binding assay for HIF-1
To measure HIF-1 DNA binding activity nuclear extracts were
subjected to a competitive colorimetric assay (TransFactor Family
Kit-HIF-1ab, BD Biosciences) according to the manufacturer’s
instruction. This method is supposed to be signiﬁcantly more sensitive
than electrophoretic mobility shift assays [16]. Here, HIF-1a/b protein
complexes bind to the HIF-1 consensus DNA binding sequence of oli-
gonucleotides coated on each well of a microplate. The speciﬁcity of
HIF-1 binding competition experiments was conﬁrmed by adding wild
type competitor oligonucleotides (500 ng) to positive control nuclear
extracts.
2.6. Realtime quantitative RT-PCR with SYBR green
RNA was isolated using TRIzol (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instruction. First-strand cDNA was
synthesized using Superscript II (Invitrogen). CDNA was quantiﬁed
in duplicate on a Rotor-Gene RG3000 (Corbett Research, Sydney,
Australia) using a SYBR green core reagent kit (Applied Biosystems)
according to the manufacturer’s instructions. PCR reactions were per-
formed in 12.5 ll volumes with 1.25 ll of the appropriate RT reactionmixture. 18S ribosomal RNA served as a reference. Primers were ob-
tained from MWG-Biotech AG (Ebersberg, Germany). The following
primers were used: the 18S forward 5 0-CCC TGT AAT TGG AAT
GAG TCC AC-3 0 and 18S reverse 5 0-GCT GGA ATT ACC GCG
GCT-3 0, the HIF-1a forward 5 0-CCA GTT ACG TTC CTT CGA
TCA GT-3 0 and the HIF-1a reverse 5 0-TTT GAG GAC TTG CGC
TTT CA-3 0, aldolase A forward 5 0-GTC CCT TCC CCC AAG TTA
TCA-3 0 and aldolase A reverse 5 0-GAC CAC GCC CTT GTC TAC
CTT-3 0, VEGF forward 5 0-CTC TAC CTC CAC CAT GCC AAG-
3 0 and VEGF reverse 5 0-AGA CAT CCA TGA ACT TCA CCA
CTT C-3 0. The primer concentrations were 300 nM each for HIF-1,
VEGF, and aldolase A as well as 100 nM for 18S. Speciﬁcity of ampli-
ﬁcation products was veriﬁed by melting curve analysis and agarose gel
electrophoresis. Relative mRNA expression of the target gene was cal-
culated with the comparative CT method. The amount of target gene
was normalized to the endogenous 18S control RNA. PCR eﬃciencies
were measured and found to be >90%.
2.7. Data analysis
The data are expressed as means ± S.E.M. from 3–4 experiments.
Statistical analysis included analysis of variance (ANOVA) and multi-
ple comparison procedures using the Student–Newman–Keul method,
or Kruskal–Wallis one-way non-parametric ANOVA on ranks if
appropriate. P values less than 0.05 were considered signiﬁcant.3. Results
3.1. IL-4 enhances hypoxic HIF-1a protein accumulation in a
dose-dependent fashion
To investigate the eﬀect of Th2 cytokines IL-4 and IL-10 on
HIF-1a protein concentrations, HT-29 cells were treated with
10 ng/ml IL-4 or IL-10 at 21% or 1% oxygen for 4 h. IL-4
signiﬁcantly increased HIF-1a protein levels during hypoxia;
this eﬀect was dose-dependent (Fig. 1). IL-10 had no eﬀect on
HIF-1a protein levels, although others have shown before that
HT-29 cells are responsive to IL-10 [17,18]. HIF-1a was not
detected during normoxia, irrespective of interleukin treat-
ment.3.2. IL-4 increased HIF-1a mRNA levels under normoxic and
hypoxic conditions
HIF-1a is regulated post-transcriptionally in hypoxia.
Hypoxia has no eﬀect on HIF-1 mRNA expression. To inves-
tigate the mechanism by which IL-4 increased hypoxia-induced
HIF-1a protein concentration, the eﬀect of IL-4 on HIF-1a
mRNA levels was measured. As expected HIF-1a mRNA
expression was similar during normoxia and hypoxia. Treat-
ment with IL-4 resulted in increased levels of HIF-1a mRNA
under both hypoxic and normoxic conditions (Fig. 2).3.3. IL-4 induced up-regulation of HIF-1a is due to increased
transcription rate
We next investigated whether the increase in HIF-1a mRNA
after IL-4 stimulation led to increased HIF-1a protein levels in
IL-4 treated hypoxic cells. HT-29 cells were pretreated with
actinomycin D, a potent transcription inhibitor, prior to stim-
ulation with IL-4 under hypoxic conditions. Pretreatment with
actinomycin D completely blocked the IL-4 induced upregula-
tion of HIF-1a mRNA (Fig. 3A). As transcriptional inhibition
prevented the IL-4 induced increase in HIF-1a mRNA,
increased transcription rate, but not increased HIF-1a mRNA
stability seems to be responsible for the higher HIF-1a mRNA
levels. Furthermore, pretreatment with actinomycin D pre-
vented IL-4 induced increase in HIF-1a protein concentration
N H H+ActD HIL4 HIL4+ActDH
IF
-1
a 
m
R
N
A
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
N
0
1
2
3
* *A 
B N                Hypoxia
ActD               +                + 
IL-4                 +       + 
HIF-1α
actin
H H+ActD HIL4 HIL4+ActD
%
 d
en
si
ty
 (n
or
m
al
iz
ed
 to
 a
ct
in
)
0
100
200
300
400
500
*
Fig. 3. Eﬀects of actinomycin D on (A) steady-state HIF-1a mRNA
levels and (B) HIF-1a protein levels in HT-29 cells. Cells were
pretreated for 20 min with actinomycin D (0.5 lg/ml) or with vehicle
only (1% DMSO), followed incubation with or without IL-4 (10 ng/ml)
under normoxic (N) or hypoxic (H) conditions. (A) RNA was isolated
and subjected to realtime RT-PCR. Means ± S.E. (n = 3). *P < 0.05.
(B) Total cell extracts were analysed by Western blotting. Density of
the HIF-1a bands was normalized to actin. Results are shown as
relative density (percentage compared with the hypoxic controls
treated with vehicle only). Means ± S.E. (n = 3). *P < 0.05.
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Fig. 1. Eﬀect of IL-4 on HIF-1a protein levels under 1% O2 (H). HT-
29 cells were incubated for 4 h with IL-4 or with vehicle only in
hypoxia (H). Untreated normoxic cells served as controls (N; 21% O2).
Total cell extracts were analysed by Western blotting. Density of the
HIF-1a bands was normalized to actin. Results are shown as relative
density (percentage compared with the hypoxic controls treated with
vehicle only). Means ± S.E. (n = 4). *P < 0.05 vs. H.
N NIL4 H HIL4H
IF
-1
 a
lp
ha
 m
R
N
A
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 N
0
1
2
3 * *
Fig. 2. Steady-state HIF-1a mRNA levels in HT-29 cells. Cells were
incubated for 4 h with IL-4 or with vehicle only in normoxia (21% O2;
N) or in hypoxia (1% O2; H). RNA was isolated and subjected to
realtime RT-PCR. Means ± S.E. (n = 3). *P < 0.05 vs. N.
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IL-4 induces HIF-1a gene transcription and thereby increases
HIF-1a protein concentration.
3.4. Blocking the PI3K pathway with LY204002 partially
inhibited IL-4 induced up-regulation of HIF-1a protein
during hypoxia
Activation of the phosphoinositol 3-kinase (PI3K) pathway
through various non-hypoxic stimuli has been shown to play a
major role in initiating HIF-1a protein expression [19,20].
Here we investigated whether activation of the PI3K pathway
is involved in IL-4 induced increase in HIF-1a protein level
during hypoxia. To block PI3K signaling, we used the speciﬁc
inhibitor LY 294002 (25 lM). This concentration has been re-
ported to be optimal for PI3K inhibition in HT-29 cells [21].
LY 294002 abolished the increase in HIF-1a protein in IL-4
stimulated hypoxic cells by as much as 60% (Fig. 4). LY294002 did not aﬀect HIF-1a protein levels in hypoxia alone.
These results suggest, that activation of the PI3K pathway
plays a role in the IL-4 induced increase in HIF-1a protein
level in hypoxia.
3.5. Neither IL-4 nor IL-10 treatment increased hypoxia induced
HIF-1a DNA-binding activity
To investigate whether increased HIF-1a protein levels in-
duced by IL-4 under hypoxic conditions, also raise HIF-1
DNA-binding activity an enzyme-linked, colorimetric DNA
binding immunosorbent assay for HIF-1 (TransFactor Family
Kit-HIF-1ab, BD Biosciences) was performed. HIF-1 DNA-
binding activity increased signiﬁcantly under hypoxic condi-
tions. Despite a substantial increase in HIF-1a protein levels
after IL-4 treatment of hypoxic cells, IL-4 did not increase
HIF-1a DNA-binding activity (Fig. 5). Experiments with IL-
4 treatment for 4 and 13 h of hypoxia gave similar results.
IL-10 did not alter HIF-1a DNA-binding activity. Speciﬁcity
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Fig. 4. Eﬀects of LY 294002 (25 lM) on HIF-1a protein levels in IL-4
treated hypoxic HT-29 cells. Cells were pretreated for 20 min with LY
294002 or with vehicle only (0.5%DMSO), followed by incubation with
or without IL-4 (10 ng/ml) under normoxic (N) or hypoxic (H)
conditions. Total cell extracts were analysed by Western blotting.
Density of theHIF-1a bandswas normalized to actin. Results are shown
as relative density (percentage compared with the hypoxic controls
treated with vehicle only). Means ± S.E. (n = 3). *P < 0.05 vs. H.
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Fig. 5. HIF-1a DNA-Binding activity in HT-29 cells. Cells were
incubated for 4 h with IL-4, IL-10, or with vehicle only in normoxia
(N) or hypoxia (H). Nuclear extracts were isolated and subjected to a
colorimetric assay. Nuclear extract from CoCl2 treated cells provided
by the manufacturer were used as positive control. Means ± S.E.
(n = 4). *P < 0.05 vs. N.
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ments. Addition of 500 ng wild type competitor oligonucleo-
tide to positive control nuclear extracts decreased the signal
up to 38%.
3.6. IL-4 or IL-10 treatment did not increase expression of the
HIF-1 a regulated genes VEGF and Aldolase A under
normoxia or hypoxia
Under normoxic conditions IL-4 did not induce the expres-
sion of the HIF-1 responsive genes VEGF and aldolase A
(results not shown). Expression of VEGF and aldolase A
increased under hypoxic conditions (Fig. 6). Although HIF-
1a protein levels were considerably higher in IL-4 treated hyp-oxic cells than hypoxic controls, IL-4 did not increase the
expression of VEGF and aldolase A in hypoxia after 4 or
13 h of exposure. This is consistent with the ﬁnding that IL-4
did not change HIF-1a DNA-binding activity under hypoxic
conditions (Fig. 5). Thus, IL-4 had no eﬀect on the transcrip-
tional activity of HIF-1 despite the increase in HIF-1a protein
levels. IL-10 had no eﬀect on HIF-1 mediated gene expression
under both normoxic and hypoxic conditions (Fig. 6).4. Discussion
In the present study, we demonstrated that the Th2 type
cytokine IL-4 increases HIF-1a protein levels in transformed
human intestinal cells during hypoxia, but not during norm-
oxia. Increased transcription of HIF-1a as well as activation
of the PI3K pathway appear to play a role in these eﬀects.
The IL-4 induced increase in hypoxic HIF-1a protein levels
did not gave rise to an up-regulation of HIF-1 DNA-binding
activity or HIF-1 dependent gene expression. Another Th2
type cytokine, IL-10, had no eﬀect on HIF-1a protein or
mRNA levels during both normoxia and hypoxia.
Recent studies have demonstrated the importance of HIF-1
in inﬂammation. HIF-1a expression is strongly increased in
inﬂammatory cells from inﬂamed tissue [22], which is thought
to be caused by the release of tumor necrosis factor (TNF)-a.
A number of studies have shown induction of HIF-1a by
TNF-a and other pro-inﬂammatory mediators under norm-
oxic conditions [6–8,23] in various cell types. Furthermore,
IL-1 has been known to increase hypoxia induced HIF-1
DNA-binding activity and HIF-1a protein concentration
[7,23]. However, the eﬀect of anti-inﬂammatory cytokines on
HIF-1a response has not been investigated yet. We chose to
study this eﬀect on intestinal epithelial cells, as the splanch-
nic mucosal microvasculature is particularly prone to micro-
circulatory disturbances [11]. Furthermore, the gut undergoes
changes in its immune status during systemic inﬂammation
and becomes a cytokine-generating organ [24]. Systemic
inﬂammation therefore exposes intestinal epithelial cells to
both hypoxia and inﬂammatory mediators.
The cytokines secreted by activated CD4 Th2 type T cells are
known to have anti-inﬂammatory properties. A number of
studies support the anti-inﬂammatory role of the Th2 cytokine
IL-4 in intestinal inﬂammation. IL-4 downregulates Th1-asso-
ciated injury [25] and ameliorates experimental colitis [26].
Furthermore, hapten-induced colitis shifts from Th1 to a
Th2 response during the resolution phase [27], suggesting
counter-inﬂammatory properties of Th2 cytokines. Recent
experimental evidence, however, also demonstrated pro-
inﬂammatory eﬀects of IL-4 on intestinal tissue [29].
The eﬀect of IL-4 on HIF-1a is diﬀerent from that of
other pro-inﬂammatory mediators in several aspects. While
the pro-inﬂammatory cytokines TNF-a, INF-c, and IL-1b all
increase HIF-1a response during normoxia [6,7,23], IL-4
increases HIF-1a protein levels only during hypoxia. IL-4
induced HIF-1a protein accumulation seems to be primarily
the result of increased HIF-1a gene expression, whereas pro-
inﬂammatory cytokines and hypoxia induce HIF-1a protein
accumulation without aﬀecting transcription of the HIF-1a
gene [6,7,30]. Only lipopolysaccharide (LPS) has been found
to increase HIF-1a mRNA levels [8]. LPS increased HIF-1a
mRNA and protein levels during normoxia, IL-4, by contrast,
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Fig. 6. Steady-state VEGF (A) and aldolase A (B) mRNA levels in HT-29 cells. Cells were incubated for 4 h with IL-4, IL-10, or with vehicle only in
normoxia (N) or hypoxia (H). RNA was isolated and subjected to realtime RT-PCR. Means ± S.E. (n = 3). *P < 0.05 vs. N.
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normoxia, increased levels of HIF-1 mRNA did not result in
higher HIF-1a protein concentrations probably because of
immediate degradation of HIF-1a protein.
Glucocorticoids, which possess anti-inﬂammatory proper-
ties, also exert their eﬀect on HIF-1 only during hypoxia
[31]. Unlike glucocorticoids, IL-4 increased HIF-1a protein
levels without aﬀecting HIF-1 transcriptional activity. Other
mediators might therefore be necessary to increase transcrip-
tional activity of IL-4 induced HIF-1a protein, resulting in en-
hanced adaptation to hypoxia. Further investigations should
address this question.
We have demonstrated that IL-4 enhances the hypoxic in-
crease in HIF-1a protein levels in transformed intestinal cells.
As intestinal epithelial cells are particularly exposed to hypoxia
and pro- and anti-inﬂammatory mediators, this observation
might be of clinical relevance. Enhanced adaptation to hypoxia
might protect intestinal epithelial cells from negative eﬀects of
hypoxia. The protective eﬀect of HIF-1a has been demon-
strated before: Karhausen and colleges have shown in murine
colitis, that increased HIF-1a levels protected these mice from
severe clinical symptoms. Activation of HIF-1 resulted in atten-
uated loss of barrier during colitis [32]. Beside of its anti-inﬂam-
matory properties, IL-4 up-regulates trefoil factor (TFF)-3
mRNA and protein in HT-29 cells. Increased levels of TFF-3
can protect the colon, as TFF peptides are important agents
in preventing mucosal damage and aiding epithelial repair
[28]. In the present study we did not investigate clinical param-
eters. Therefore the clinical eﬀect of IL-4 induced up-regulation
HIF-1a protein should be examined in vivo in further studies.
Complete inhibition of IL-4 induced HIF-1a gene transcrip-
tion almost completely inhibited IL-4 mediated induction
of HIF-1a protein. However, other pathways may also be
involved. Two other major phosphorylation pathways are
involved in hypoxic and ligand-induced activation of HIF-1
[33]. The mitogen-activated protein kinase (MAPK) increases
the transactivation ability of HIF-1 [34], while leaving HIF-
1a protein levels unaﬀected. In contrast, the activation of the
PI3K pathway has been shown to increase HIF-1a protein
levels [35,36]. Both, HIF-1a protein stabilization [37] and
increased HIF-1a protein production seem to be inﬂuenced
by the PI3K pathway, while HIF-1a mRNA expression
remains unaﬀected [38]. As IL-4 increased hypoxic HIF-1aprotein levels in the present study, we investigated the involve-
ment of the PI3K pathway. Inhibition of PI3K by LY 294002
partially inhibited IL-4 induced hypoxic HIF-1a protein accu-
mulation. Therefore the PI3K pathway appears to play a role
in the observed eﬀect of IL-4 on HIF-1a protein levels, inde-
pendently from increased HIF-1a mRNA levels. The mecha-
nisms identiﬁed are diﬀerent from hypoxic up-regulation of
HIF-1a. Thus hypoxic up-regulation and IL-4 mediated induc-
tion of HIF-1a might work synergistically.
In summary, we have shown herein that the Th2 cytokine
IL-4 enhances the hypoxic increase in HIF-1a protein levels
without aﬀecting transcriptional activity of HIF-1a. Mecha-
nisms involved in the IL-4 induced accumulation of HIF-1a
protein in hypoxia are increased HIF-1a gene transcription
as well as the PI3K/Akt pathway.Acknowledgements: This study was supported by the Ministerium fu¨r
Wissenschaft und Forschung of the county NRW/Germany Lise-Meit-
ner Grant 134.1.06.01.05/04 and the University of Muenster/Germany
IMF Grant SC 220402.References
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